

VantagePoint – BizInt Smart Charts Edition to be Released in Early 2012

Orange, California - 9 November 2011

BizInt Solutions, Inc. is pleased to announce an agreement with Search Technology, Inc. to develop and market a custom version of VantagePoint for use by BizInt Smart Charts customers.

VantagePoint – BizInt Smart Charts Edition will import files exported by BizInt Smart Charts for Drug Pipelines or BizInt Smart Charts for Patents, using a custom version of the new XML Smart Data Exchange format. BizInt Smart Charts users can apply data cleaning and user-managed thesaurus tools in VantagePoint and then export cleaned and normalized fields back to BizInt Smart Charts.

“I am very excited by the potential of VantagePoint to offer BizInt Smart Charts users powerful features for normalizing and enhancing data in multi-database reports,” said Diane Webb, President, BizInt Solutions, Inc. “Especially used in conjunction with our new BizInt Smart Charts Reference Rows utility, VantagePoint will help our users create truly meaningful multi-database reports, with consistent values across databases.”

VantagePoint – BizInt Smart Charts Edition will contain VantagePoint’s core analytics suite including market-leading Data Cleanup, Thesaurus, Record Classifications, My Keywords, and interactive analytical visualizations. Data exchange between the two tools will be simplified to make it easy to move data back and forth, allowing the user to concentrate on analysis and reporting, rather than managing data flow.

“VantagePoint and BizInt Smart Charts are an ideal pair for the Information Professional – powerful analytics with flexible data integration and reporting,” said Paul Frey, President, Search Technology, Inc., developers of VantagePoint. “We are delighted to work with BizInt Solutions to bring this streamlined solution to the Drug Pipeline and Patent information markets.”

VantagePoint – BizInt Smart Charts Edition will be sold by BizInt Solutions as part of a BizInt Smart Charts license. Annual license pricing will be \$3000 for the first user and \$1600 for additional users in the same license. The expected release date is 1Q 2012.

Contact:

Diane Webb
BizInt Solutions, Inc.
1.714.289.1000
products@bizcharts.com
<http://www.bizcharts.com>


Paul Frey
Search Technology, Inc.
1.770.441.1457
VantagePoint@searchtech.com
<http://www.TheVantagePoint.com>



Using BizInt Smart Charts and VantagePoint with the XML Smart Data Exchange (Beta)

BizInt Smart Charts and VantagePoint users can start using the XML Smart Data Exchange format in beta to export data to VantagePoint and then reimport analyzed data in BizInt Smart Charts.

1. Create your Smart Charts report in Version 3.4 and then export using the “XML-Smart Data Exchange [BETA] chart only” option under File | Export. Keep the BizInt Smart Charts file open for Step 7 below.
2. In VantagePoint, import the .xml file using the Import XML Smart Data Exchange icon on the VP toolbar.
3. Use the data cleaning and user-managed thesaurus tools in VantagePoint to create new fields.
4. Export the new fields back to BizInt Smart Chart by selecting the Export XML Smart Data Exchange icon on the VantagePoint toolbar.
5. In step 2 of the VantagePoint Export Wizard, select “<<Remove All”, then add the “recordID” and the VP created fields you wish to export. *Do not export all fields or you will end up with duplicate fields in Smart Charts.*
6. In step 3 of the VantagePoint Export Wizard, select which BizInt Smart Charts product you are exporting to, the “Launch Application” radio button, and Finish.
7. BizInt Smart Charts will ask you to select the chart to which you wish to add the data. The fields you exported from VantagePoint will be added to the chart as “User” fields.



	Trial Title	Database	Phase	Phase (Normalized)	Sponsor(s)	Trial Status	Trial Status (Normalized)
96.1	DPP4 Inhibitor in the Hospital	ClinicalTrials.Gov	Phase 4	Phase 4	Emory University Merck	Not yet recruiting	Planned
96.2	DPP-IV Inpatient Trial	ClinicalTrials.Gov	Phase 4	Phase 4	Emory University Merck	Active, not recruiting	Active, Not Recruiting
96.3	Randomized Controlled Study of DPP4 Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes.	Citeline TrialTrove	IV	Phase 4	Emory University Hospital - Atlanta Merck & Co.	Planned	Planned
96.4	Randomized Controlled Study of DPP4 Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes.	Adis Clinical Trials Database	IV	Phase 4	Merck & Co	Active, no longer recruiting	Active, Not Recruiting
97.1	Changes in Bone Turnover With Increased Incretin Hormone Exposure	ClinicalTrials.Gov	Phase 4	Phase 4	University of Alabama at Birmingham	Recruiting	Open, Recruiting
97.2	Changes in Bone Turnover With Increased Incretin Hormone Exposure (UAB Diabetes Research and Training Center Pilot and Feasibility Study)	Citeline TrialTrove	IV	Phase 4	University of Alabama, Birmingham	Open	Open, Recruiting

	# Records	# Instances	Highest Phase (1)
1	131	131	Preclinical
2	90	90	Biological Testing
3	64	64	No Development Reported
4	57	57	Phase 2
5	56	56	Phase 1
6	36	36	Discontinued
7	29	29	Phase 3
8	23	23	Launched
9	9	9	Phase 1/2
10	2	2	Technology
11	1	1	Clinicals
12	1	1	Preregistration

Highlighted in yellow are columns created by VantagePoint – normalized phases and trial status fields in a clinical trials chart (at left) and three variations on normalized phases in a pipeline chart (below).

	Product	Common Drug Name	Database	Highest Phase	Highest Phase - VP (Excel)	Highest Phase - VP (Arabic)	Highest Phase - VP (Roman)
13	AC-480	AC 480	Thomson Pharma	Phase 2 Clinical	2 Phase 2	Phase 2	Phase II
14	BMS 599626	AC 480	Adis R&D Insight	Phase II	2 Phase 2	Phase 2	Phase II
15	BMS-599626	AC 480	Citeline Pipeline	No Development Reported	8 No Development Reported	No Development Reported	No Development Reported
16	AC-480 (free base)	AC 480	Thomson Reuters Integrity Compounds	Phase I	1 Phase 1	Phase 1	Phase I
17	AC-480	AC 480	Citeline Pipeline	Phase II	2 Phase 2	Phase 2	Phase II
18	AC 480	AC 480	IMS R&D Focus	Phase II	2 Phase 2	Phase 2	Phase II
19	Ad5-ratNeuECD.TM	Ad5-ratNeuECD.TM	Thomson Reuters Integrity Compounds	Preclinical	0 Preclinical	Preclinical	Preclinical
20	aderbasib (pINN)	aderbasib	IMS R&D Focus	Phase II	2 Phase 2	Phase 2	Phase II
21	ADL-681	ADL-681	Citeline Pipeline	No Development Reported	8 No Development Reported	No Development Reported	No Development Reported
22	APT 101	APT 101	IMS R&D Focus	Suspended	7 Discontinued	Discontinued	Discontinued
23	AP-23464	AP-23464	Citeline Pipeline	Discontinued	7 Discontinued	Discontinued	Discontinued
24	apricoxib (pINN)	apricoxib	IMS R&D Focus	Phase II	2 Phase 2	Phase 2	Phase II
25	AEE-788	AEE 788	Thomson Pharma	No Development Reported	8 No Development Reported	No Development Reported	No Development Reported
26	AEE-788	AEE 788	Citeline Pipeline	No Development Reported	8 No Development Reported	No Development Reported	No Development Reported
27	AEE 788	AEE 788	Adis R&D Insight	Phase I	1 Phase 1	Phase 1	Phase I
28	NVP-AEE-788	AEE 788	Thomson Reuters Integrity Compounds	Phase I/II	1 Phase 1/2	Phase 1/2	Phase I/II